# New Study Confirms Capsugel® Enprotect® Capsules Deliver Robust Gastric Integrity Under Both Fasted and Fed Conditions

- Link: https://www.thailand-business-news.com/pr-news/new-study-confirms-capsugel-enprotect-capsules-deliver-robust-gastric-integrity-under-both-fasted-and-fed-conditions
- Published: 2026-08-17T10:45:00+07:00
- Author: PR Newswire

SEOUL, South Korea, Aug. 14, 2026 /PRNewswire/ — Enteric capsules are widely used
to protect acid-sensitive compounds and to delay drug release until intestinal entry.
However, evidence supporting their gastric integrity under physiologically relevant
fed-state conditions remains limited, as most data rely on conventional static _in
vitro_ dissolution tests.

In this [study](https://www.sciencedirect.com/science/article/pii/S0939641125003406?via%3Dihub),
the authors from Bioneer A/S, the University of Copenhagen, and Lonza Capsugel evaluated
the gastric integrity of their enteric capsules – Capsugel® Enprotect® capsules,
using the Dynamic Gastrointestinal Model (DGM), which simulates the physical, hydrodynamic,
and biochemical conditions of the human gastrointestinal tract under fasted and 
fed states. The DGM simulated key physiological factors such as gastric motility,
pH changes, digestive secretions, and gastric emptying patterns.

Capsugel^(®) Enprotect^(®) capsules, offer a next-generation enteric delivery solution
designed to protect acid-sensitive APIs and enable targeted release in the small
intestine. These capsules have been developed using a first-of-its-kind manufacturing
process. The bi-layered capsule manufacturing technology allows target delivery 
of APIs to the distal small intestine without the need for post-filling coating 
excipients, which accelerates the drug manufacturing and development processes. 
They avoid exposure to heat and solvents to protect against degradation for some
APIs. 

[[

To evaluate this performance, researchers filled the capsules with caffeine, a well-
characterized model compound, and tested them under three conditions:

 ◦ Fasted state
 ◦ Light meal (~500 kcal)
 ◦ High-fat FDA meal (~900 kcal)

Results showed caffeine‑filled **Capsugel® Enprotect® capsules** **remained intact
throughout gastric transit across all tested conditions**, with release occurring
only after intestinal entry. No caffeine was detected in stomach samples, indicating
that the capsules did not prematurely release their contents. The capsules only 
disintegrated after entering the intestinal compartment, confirming their gastro-
resistant properties. The capsules remained in the stomach for approximately 29 
minutes in the fasted state, 147 minutes after the light meal, and 243 minutes following
the high-fat meal. Despite this prolonged exposure, the capsules maintained their
structural integrity.

Importantly, DGM‑based predictions of gastric residence time, capsule disintegration,
and pharmacokinetic profiles closely aligned with previously published human MRI
and salivary tracer data in the fasted state and after a light meal. One of the 
study’s most significant findings was that even under the challenging conditions
of a high-fat meal, where gastric pH remained elevated for an extended period and
stomach emptying was substantially delayed, the capsules still remained intact. 
The study also indicates that capsule floating behavior and the presence of an acidic"
acid pocket" in the stomach may have helped preserve capsule integrity despite the
less acidic environment.

Overall, these findings confirm the **robust gastro****‑****resistant performance
of Capsugel® Enprotect® capsules** and highlight the value of biorelevant _in vitro_
tools to predict oral dosage form behavior beyond standard dissolution testing.

**Join Us at CPHI Korea 2026 and Discover the Future of Targeted Ingredient Delivery**

As one of Asia’s premier pharmaceutical and nutraceutical industry events, **CPHI
Korea 2026 **connects pharma and nutraceutical leaders across Asia to discover emerging
technologies, exchange industry insights, and build partnerships driving innovation
in health and nutrition. A key highlight at this year’s event will be **Capsugel
® Enprotect® capsules**, our innovative enteric capsule technology designed to provide
reliable gastric protection and targeted ingredient delivery without the need for
additional enteric coating processes.

Visit us at **Booth K15, COEX, Seoul, South Korea, 25-27 August 2026**, and discover
how Capsugel® Enprotect® capsules and our advanced delivery technologies can help
bring your next innovation to market faster and more effectively.

[**For more information on Capsugel® Enprotect® capsules, please visit us at CPHI Korea.**](https://www.thailand-business-news.com/pr-news/solutions.apac@lonza.com?subject=Enquiry%20about%20Capsugel%C2%AE%20Enprotect%C2%AE%20capsules)

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [New Study Confirms Capsugel® Enprotect® Capsules Deliver Robust Gastric Integrity Under Both Fasted and Fed Conditions ](http://www.prnasia.com/story/archive/5026566_AE26566_0?rand=184833)
